Pemfexy

See full labeling. Increased risk of myelosuppression without vitamin supplementation. Permanently discontinue if recurrent Grade 3 or 4 myelosuppression or non-hematologic toxicity after two dose reductions, Grade 3 or 4 neurologic toxicity, severe/life-threatening skin toxicity, interstitial pneumonitis, or signs of radiation recall occur. Obtain CBCs at the beginning of each cycle. Do not start a treatment cycle unless ANC is ≥1500cells/mm³, platelets ≥100,000cells/mm³, recovery of non-hematologic toxicity to Grade 0–2. Withhold if acute onset of new or progressive unexplained pulmonary symptoms occur. Monitor CBCs, platelets, renal function prior to each dose and during treatment. Renal impairment (CrCl <45mL/min). Severe third space fluid. Embryo-fetal toxicity. Advise to use effective contraception during and for 6 months (females of reproductive potential) or 3 months (males w. female partners) after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).